Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike

Rhea-AI Filing Summary

Tenaya Therapeutics director Williams R. Sanders received a grant of stock options for 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were awarded under the company’s 2021 Equity Incentive Plan. They vest in full on May 28, 2027, or earlier if the next annual stockholder meeting occurs before that date, provided Sanders continues as a service provider.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Williams R Sanders

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	120,000	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 120,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 120,000 options Exercise price: $0.7989 per share Underlying shares: 120,000 shares +2 more

5 metrics

Options granted 120,000 options Stock Option (Right to buy) grant to director

Exercise price $0.7989 per share Strike price for the 120,000 options

Underlying shares 120,000 shares Common stock underlying the options

Vesting date May 28, 2027 Full vesting date, subject to continued service

Expiration date May 27, 2036 Option expiration if unexercised

Key Terms

Stock Option (Right to buy), Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan, exercise price, vesting

4 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan financial

"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."

exercise price financial

"conversion_or_exercise_price: 0.7989"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams R Sanders

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.7989	05/28/2026		A		120,000		05/28/2027(1)	05/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tenaya Therapeutics (TNYA) director Williams R. Sanders report on this Form 4?

Williams R. Sanders reported receiving a grant of stock options for 120,000 shares of Tenaya Therapeutics common stock. These options were awarded as compensation under the company’s 2021 Equity Incentive Plan and represent a non-cash acquisition of derivative securities.

What is the exercise price of the new Tenaya Therapeutics (TNYA) stock options?

The newly granted stock options to director Williams R. Sanders have an exercise price of $0.7989 per share. This is the price he would pay to purchase Tenaya Therapeutics common stock if he exercises the options after they vest, subject to the plan’s terms.

When do Williams R. Sanders’ Tenaya Therapeutics (TNYA) options vest?

The stock options granted to Williams R. Sanders vest in full on May 28, 2027. They can instead vest earlier on the day immediately before the next annual stockholder meeting after the grant date, if he remains a service provider through that vesting date.

How many Tenaya Therapeutics (TNYA) options does Williams R. Sanders hold after this transaction?

Following this grant, Williams R. Sanders holds 120,000 stock options as reported in the Form 4. These options are directly owned and are tied to an equivalent number of Tenaya Therapeutics common shares, subject to vesting and exercise conditions in the equity plan.

Are the Tenaya Therapeutics (TNYA) options granted to Williams R. Sanders immediately exercisable?

The options granted to Williams R. Sanders are not immediately exercisable because they are subject to vesting. They vest in full by May 28, 2027, or earlier before the next annual meeting, contingent on his continued service to Tenaya Therapeutics.